Back to browse results
BCG vaccination is associated with reduced malaria prevalence in children under the age of 5 years in sub-Saharan Africa
Authors: Mike LT Berendsen, Sjors WL van Gijzel, Jeroen Smits, Quirijn de Mast, Peter Aaby, Christine S Benn, Mihai G Netea, and Andre JAM van der Ven
Source: BMJ Global Health, 4: e001862; DOI:10.1136/ bmjgh-2019-001862
Topic(s): Child health
Children under five
Country: Africa
  Multiple African Countries
Published: NOV 2019
Abstract: Introduction Malaria continues to be a major cause of morbidity and mortality in sub-Saharan Africa (SSA) without effective interventions. Bacillus Calmette-Guérin (BCG) vaccine possesses protective non-specific effects, which extend beyond protection against tuberculosis. This study explores whether BCG is associated with protection against malaria in children under the age of 5 years in SSA. Methods We used data from the Demographic Health Survey programme, including 34206 children from 13 SSA countries. BCG status was taken from vaccination cards when present; if not, mother’s recall was used. Presence of malaria was defined as a positive rapid diagnostic test. Maternally reported presence or absence of fever in the previous two weeks defined symptomatic status. Multilevel logistic regression was used to account for the two-stage cluster sampling method. Results Of the 34206 children, 12325 (36.0%) children were malaria positive and 29766 (87.0%) were BCG vaccinated. After correction for relevant child, maternal and household factors, BCG vaccination was associated with a lower malaria prevalence (adjusted OR (aOR)=0.94, 95% CI 0.90 to 0.98), especially among children of whom BCG information was retrieved from a vaccination card (aORcard=0.88, 95% CI 0.82 to 0.94). Restricting the analysis to children from regions with suboptimal BCG coverage increased the association (aORcard=0.81, 95% CI 0.73 to 0.89). We observed an increasingly beneficial association with each month of age of the child (aORcard=0.996, 95% CI 0.993 to 0.999). BCG associations were similar for asymptomatic (aORcard=0.86, 95% CI 0.81 to 0.92) and symptomatic (aORcard=0.89, 95% CI 0.78 to 1.01) malaria. Conclusions BCG vaccination is associated with protection against malaria. This protection is highest in regions with suboptimal BCG coverage. These results indicate a possible role for timely BCG vaccination in the protection of malaria and its elimination by reducing the transmission reservoir. If confirmed in further research, our findings have substantial implications for global efforts to reduce malaria burden.